Maternal humoral factors associated with perinatal human immunodeficiency virus type-1 transmission in a cohort from Kigali, Rwanda, 1988-1994

Journal of Infection

Volumn 39, Issue 3, 1999, Pages 213-220

  Tranchat, C ^a   Van De Perre, P ^b   Simonon Sorel, A ^b   Karita, E ^b   Benchaib M ^c   Lepage, P ^d   Desgranges, C ^a   Boyer, V ^a   Trepo C ^a  

^a INSERM   (France)

^b Lab Natl de Ref   (Rwanda)

^c Lab de Biologie de la Reproduction   (France)

^d Centre Hospitalier Universitaire de Kigali   (Rwanda)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN P24; CD4 ANTIGEN; CD8 ANTIGEN; GLYCOPROTEIN GP 41;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; RWANDA; VERTICAL TRANSMISSION; VIRUS LOAD; VIRUS NEUTRALIZATION; VIRUS TRANSMISSION;

EID: 0033378499     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-4453(99)90052-X     Document Type: Article

References (32)

1. Sperlling RS, Shapiro DE, Coombs RW et al. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. N Engl J Med 1996; 335: 1621-1629.
2. Bryson YJ. Perinatal HIV-I transmission: recent advances and therapeutic interventions. AIDS 1996; 10: 33-42.
3. Van de Perre P. Simonon A. Msellati P. Post-natal transmission of human immunodeficiency virus type 1 from mother to infant. N Engl J Med 1991; 325: 593-598.
4. World Health Organization: Report on the global HIV/AIDS Epidemic December 1997, 1-28.
5. Report of a consensus Workshop, Sienna. Italy, January 17-18. Maternal factors involved in mother-to-child transmission of HIV-1. J Acquir Immune Defic Syndr 1992; 5: 1019-1029.
6. Weiser B, Nachman S, Tropper P et al. Ouantitation of human immunodeficiency virus type 1 during pregnancy: Relationship of viral titer to mother-to-child transmission and stability of viral load. Proc Nad Acad Sci USA 1994; 91: 8037-8041.
7. Fang G, Burger H, Grimson R et al. Maternal plasma human immunodeficiency virus type 1 RNA level: a determinant and projected threshold for mother-to-child transmission. Proc Natl Acad Sci USA 1995; 92: 12100-12304.
8. Cao Y, Krogstad P, Korber BT et al. Maternal HIV-1 viral load and vertical transmission of infection: the ariel project for the prevention of HIV transmission from mother to infant. Nat Med 1997; 3: 549-552.
9. Erb P, Krouchi S. Bergin D et al. Quantitative anti-p24 determinations can predict the risk of vertical transmission. J Acquir Immune Defic Synd 1994; 7: 261-264.
10. Scarlatti G, Albert J, Rossi P et al. Mother-to-child transmission of human immunodeficiency virus type 1: correlation with neutralizing antibodies against primary isolates. J Infect Dis 1993; 168: 207-210.
11. Lallemant M, Baillou A, Lallemant-Le Coeur S et al. Maternal antibody response at delivery and perinatal transmission of human immunodeficiency virus type 1 in African women. Lancet 1994; 343: 1001-1005.
12. Rossi P, Moschese V, Broliden PA et al. Presence of maternal antibodies to human immunodeficiency virus type 1 envelope glycoprotein gp120 epitopes correlates with the uninfected status of children born to seropositive mothers. Proc Natl Acad Sci USA 1989; 86: 8055-8058.
13. Parekh BS, Shaffer X, Pau CP et al. Lack of correlation between maternal antibodies to V3 loop peptides of gp120 and perinatal HIV-1 transmission. AIDS 1991;5:1179-1184.
14. Halsey KA, Markham R, Wahren B, Boulos R, Rossi P, Wigzell H. Lack of association between maternal antibodies to V3 loop peptides and maternal-infant HIV-1 transmission. J Acquir Immune Defic Syndr 1992; 5: 153-157.
15. Robertson CA, Moq JYQ, Froebel KS et al. Maternal antibodies to gp120 V3 sequences do not correlate with protection against vertical transmission of human immunodeficiency virus. J Infec Dis 1992; 166: 704-709.
16. Lepage P, Dabis F, Hitimana D-G et al. Perinatal transmission of HIV-1: lack of impact of maternal HIV infection on characteristics of live births and on neonatal mortality in Kigali, Rwanda. AIDS 1991; 5: 295-300.
17. Lepage P, Van De Perre P, Msellati P et al. Mother-to-child transmission of human immunodeficiency virus type 1 (HIV-1) and its determinants: a cohort study in Kigali, Rwanda. Am J Epidemiol 1993; 137: 589-599.
18. Barin F, Lahbabi Y, Buzelay L et al. Diversity of antibody binding to V3 peptides representing consensus sequences of HIV-1 genotypes A to E: An approach for HIV-1 serological subtyping. AIDS Res Hum Retroviruses 1996; 12: 1279-1289.
19. Audoly G, Fillon S, Pinay P, Desgranges C. In Vivo and in Vitro sequence diversity of the V3 Env Region of HIV Type 1 from Ivory coast. AIDS Res Hum Retroviruses 1996; 12: 1073-1075.
20. Chargelegue D, Colvin BT, O'Toole CM. A 7-year analysis of anti-Gag (p17 and p24) antibodies in HIV-1 seropositive patients with hemophilia: immunoglobulin G titer and avidity are earlier predictors of clinical course. AIDS 1993; 7 (suppl 2): S87-S90.
21. Chesebro B, Wehrly K, Nishio J, Perryman S. Macrophage-tropic human immunodeficiency virus isolates from different patients exhibit unusual V3 envelope sequence homogencity in comparison with T-cell-tropic isolates: definition of critical amino acids involved in cell tropism. J Virol 1992; 66: 6547-6554.
22. Montefiori D, Pantaleo G, Fink L et al. Neutralizing and infectionenhancing antibody responses to human immunodeficiency virus type 1 in long-term non-progressors. J Infect Dis 1996; 173: 60-67.
23. Reed LJ, Muench H. A simple method of estimated fifty percent end points. Am J Med Hyg 1938; 27: 493-497.
24. Howell DN, Andoretti JR, Cresswell P. Natural killing target antigens as inducers of Interferon: studies with an immunoselected, naturalkilling-resistant human T-lymphoblastoid cell line. J Immunol 1985; 134: 971-976.
25. Baum LL, Cassutt KJ, Knigge K et al. HIV-1 gp120-specific antibody-dependent cell-mediated cytotoxicity correlates with rate of disease progression. J Immunol 1996; 157: 2168-2173.
26. Chargelegue D, Stanley CM, O'Toole CM, Colvin BT, Steward MW. The absence or loss of antibodies of high affinity to human immunodeficiency virus (HIV) is associated with disease progression in HIV-1 infected patients. J Infec Dis 1995; 172: 897-898.
27. Goedert J, Dublin S. Perinatal transmission of HIV type 1: Associations with maternal anti-HIV serological reactivity. AIDS Res Hum Retroviruses, 1994; 10: 1125-1134.
28. Ljunggren K, Moschese V, Broliden PA et al. Antibodies mediating cellular cytotoxicity and neutralization correlate with a better clinical stage in children born to human immunodeficiency virus infected mothers. J Inject Dis 1990; 161: 198-202.
29. Jenkins M, Landers D, Williams-Herman D et al. Association between anti-human immunodeficiency virus type 1 (HIV-1) antibody-dependent cellular cytotoxicity antibody titers at birth and vertical transmission of HIV-1. J Infect Dis 1994; 170: 308-312.
30. Black KP, Cummins JE and Jackson S. Serum and secretory IgA from HIV-Infected individuals mediate antibody-dependent cellular cytotoxicity. Clin Immunol Inmnmopath. 1996; 81: 182-190.
31. Fang G, Burger H, Grimson R et al. Maternal plasma human immunodeficiency virus type 1 RNA level: A determinant and projected threshold for mother-to-child transmission. Proc Natl Acad Sc USA 1995; 92: 12100-12104.
32. Mabondzo A, Rouvier P, Raoul H et al. Relationships between humoral factors in HIV-1 infected mothers and the occurrence of HIV infection in their infants. Clin Exp Immunol 1995; 102: 476-480.